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Abstract
The cJun N-terminal kinases (JNKs; JNK1, JNK2, and JNK3) promote degenerative processes after neuronal injury and in
disease. JNK2 and JNK3 have been shown to promote retinal ganglion cell (RGC) death after optic nerve injury. In their
absence, long-term survival of RGC somas is signiﬁcantly increased after mechanical optic nerve injury. In glaucoma,
because optic nerve damage is thought to be a major cause of RGC death, JNKs are an important potential target for
therapeutic intervention. To assess the role of JNK2 and JNK3 in an ocular hypertensive model of glaucoma, null alleles
of Jnk2 and Jnk3 were backcrossed into the DBA/2J (D2) mouse. JNK activation occurred in RGCs following increased
intraocular pressure in D2 mice. However, deﬁciency of both Jnk2 and Jnk3 together did not lessen optic nerve
damage or RGC death. These results differentiate the molecular pathways controlling cell death in ocular hypertensive
glaucoma compared with mechanical optic nerve injury. It is further shown that JUN, a pro-death component of the
JNK pathway in RGCs, can be activated in glaucoma in the absence of JNK2 and JNK3. This implicates JNK1 in
glaucomatous RGC death. Unexpectedly, at younger ages, Jnk2-deﬁcient mice were more likely to develop features of
glaucomatous neurodegeneration than D2 mice expressing Jnk2. This appears to be due to a neuroprotective effect of
JNK2 and not due to a change in intraocular pressure. The Jnk2-deﬁcient context also unmasked a lesser role for Jnk3
in glaucoma. Jnk2 and Jnk3 double knockout mice had a modestly increased risk of neurodegeneration compared
with mice only deﬁcient in Jnk2. Overall, these ﬁndings are consistent with pleiotropic effects of JNK isoforms in
glaucoma and suggest caution is warranted when using JNK inhibitors to treat chronic neurodegenerative conditions.

Introduction
Glaucoma is a common neurodegenerative disease that
causes vision loss, affecting millions of people worldwide1.
Glaucomatous degeneration includes loss of retinal
ganglion cell (RGC) somas in the retina and loss of their
axons, which extend from the retina into the optic nerve
and brain. In glaucoma, RGC axons show early signs of
damage in the lamina, the region where RGC axons exit
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the eye2–6. Damage at this site is important because it may
trigger the molecularly distinct degeneration processes
that occur on each side of this site7–10. In the DBA/2J (D2)
mouse model of glaucoma, genetically disrupting Bax
prevents loss of RGC somas (RGC death) and their axons
up to the lamina; however, it does not stop degeneration
of the optic nerve outside of the eye and distal to this site
of injury8. Furthermore, the expression of WldS, a mutation that protects against axonal degeneration, can curb
early damage to RGC axons in the lamina11 and protect
RGCs and the optic nerve4,11. Thus, identifying the
molecular mechanism(s) that leads to progressive axon
damage in the lamina is an important step toward
developing neuroprotective glaucoma treatments.
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Consistent with speciﬁc JNK signaling pathway members
causing RGC death, disrupting the upstream kinase dual
leucine zipper kinase (DLK encoded by Map3k12), or the
downstream JNK target JUN, lessens RGC death after
mechanical optic nerve injury13–18. JNK itself is a product
of three distinct mitogen-activated protein kinase genes
(Mapk8, Mapk9, and Mapk10, encoding JNK1, JNK2, and
JNK3, respectively, and referred to as Jnk1, Jnk2, and Jnk3
in this article), all of which are expressed in the nervous
system19. DLK and JUN are linked in the axon injuryinduced RGC death pathway by JNK2 and JNK314,17. The
combined absence of JNK2 and JNK3 prevents JUN
activation and RGC death after mechanical optic nerve
injury similar to deﬁciencies in Map3k12 or Jun. It is
hypothesized that a similar cell death pathway is activated
by axon damage in the lamina that occurs in glaucoma.
Jun deﬁciency has been recently shown to lessen RGC
death in D2 mice with glaucoma15 and other molecules in
the JNK signaling pathway are implicated in glaucoma as
well20–22. Thus, to better understand the function of JNKs
in glaucoma, we tested the function of JNK2 and JNK3 in
DBA/2J mice, an ocular hypertensive model of glaucoma23–26.

Results
Fig. 1 JNK pathway genes associated with axon injury in RGCs
are expressed and activated during D2 glaucoma at 9 months of
age. a Publically available RNA-sequencing data sets from RGCs were
assessed for expression of a subset of JNK signaling pathway genes
implicated in axon injury. RGCs from a group of D2 eyes with ocular
hypertension, but not optic nerve damage were compared with RGCs
from control D2-Gpnmb+ eyes that do not have high intraocular
pressure or develop glaucoma. The D2 eyes analyzed here belong to
the group of eyes with the earliest detected changes in this model
(Group 2,29). The Tukey-style box plots were generated in R. The thick
bar represents median expression level and the hinges correspond to
the ﬁrst and third quartiles. Whiskers represent 1.5 × the interquartile
range, with outlying data points plotted individually. Expression level
is shown as log counts per million (log2CPM). Signiﬁcant differences in
expression of Jnk2 and Jun were detected. b Phosphorylated S63 panJNK immunoreactivity (pJNK, red) in ocular hypertensive (D2) and
normotensive (D2-Gpnmb+) eyes was assessed by ﬂuorescence in
cross-sections that include the retina and the optic nerve head (ONH).
The nerve ﬁber layer (NFL) is ﬁlled by RGC axons as they extend
toward the ONH. DAPI (blue) labeling of nuclei was used as a
counterstain. c Phosphorylated JUN immunoreactivity (pJUN, red) in
the ganglion cell layer was assessed by ﬂuorescence in retinal ﬂat
mounts with DAPI (blue) used as a counterstain. Representative
images from ocular hypertensive (D2) and normotensive (D2Gpnmb+) eyes are shown. *FDR < 0.05. Scale bar: 50 μm b, 25 μm c

The cJun N-terminal kinase (JNK) signaling pathway
regulates how various neurons respond to axon damage12.
In RGCs, severe axon trauma activates a speciﬁc subset of
JNK signaling pathway members ahead of cell death.
Ofﬁcial journal of the Cell Death Differentiation Association

IOP elevation activates JNK signaling in the retina and
optic nerve

Using D2 and D2-Gpnmb+ mice, we assessed whether
RGCs expressed JNK signaling pathway genes during the
window of ocular hypertension in D2 mice. By 9 months
of age (mos), most D2 eyes have ongoing periods of elevated intraocular pressure (IOP), but typically no optic
nerve damage or RGC death25. At this age, many eyes
have gene expression differences compared with agematched D2-Gpnmb+ eyes that do not develop high IOP
and glaucoma4,27–30. Previously, RNA-seq-based transcriptomes of RGCs puriﬁed from D2 and D2-Gpnmb+
eyes at 9 mos of age were assembled29. In ocular hypertensive eyes, RGCs express a number of JNK signaling
pathway genes previously implicated in the axon injuryinduced RGC death pathway (Fig. 1a). A signiﬁcant difference in the expression of Jnk2 and Jun exists between
D2 and D2-Gpnmb+ RGCs (false discovery rate (FDR) <
0.05).
To further examine JNK signaling in glaucoma, we
determined if JNK and JUN were phosphorylated in the
retina using immunohistochemistry (pJNK and pJUN,
respectively, phosphorylation induces an activated state).
At 9 mos of age, pJNK was present in the nerve ﬁber layer
and optic nerve head (ONH, Fig. 1b) in D2 eyes, but was
undetectable in control D2.Gpnmb+ eyes. pJUN-positive
cells were detectable throughout the ganglion cell layer at
10 mos in D2 eyes, but not in D2.Gpnmb+ eyes (Fig. 1c).
These data are consistent with recent ﬁndings, which
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Fig. 2 Jnk genotype has no affect on iris disease. Images of eyes were taken using a slit lamp biomicroscope. a Representative broad beam
images demonstrating similar iris abnormalities in mice of all genotypes. b Representative images demonstrating the similar transillumination defects
resulting from iris depigmentation in D2, D2.Jnk2−/−, and D2.Jnk3−/− mice

showed pJUN in TUJ1 + RGCs in glaucomatous DBA/2J
mice15. Together, these data indicate that the JNK signaling pathway responds to elevated IOP with changes in
both expression level and activation state of key
molecules.

decrease in this model25. Declining IOP was most evident
in D2.Jnk2−/− mice compared with controls; however, this
difference was not signiﬁcant (P = 0.052). Overall, these
data indicate that deletion of Jnk2 or Jnk3 does not alter
the iris disease and IOP insult in D2 mice.

Jnk2 and Jnk3 deﬁciencies do not prevent pigment disease
or IOP elevation in DBA/2J mice

Jnk2 deﬁciency increases susceptibility to glaucomatous
optic nerve damage

Ocular hypertension in D2 mice occurs secondary to a
pigment dispersing iris disease23,25. D2 mice carrying null
alleles of Jnk2 and Jnk3 were used to test the role of JNK2
and JNK3 in glaucoma and were maintained in a single
mouse colony. As no haploinsufﬁciency induced phenotypes have been reported for Jnk2 and Jnk3, D2 mice with
one or more functional copies (+/+ or +/−) of both Jnk2
and Jnk3 were grouped together as control mice in this
study. D2.Jnk2−/− mice were either wild-type or heterozygous for Jnk3. Similarly, D2.Jnk3−/− mice were either
wild-type or heterozygous for Jnk2. Eyes of all genotypes
were carefully assessed for the iris disease and IOP elevation. No differences in iris disease occurred between
genotypes (Fig. 2). The iris disease in eyes of all genotypes
(n = 40 eyes/group) was readily apparent between 6 and 7
mos and most eyes had severe iris disease by 12 mos.
Consistent with the iris disease, ocular hypertension
occurred in mice of all genotypes as measured between 8
and 12 mos (Fig. 3). In all groups of mice, IOP distributions were closely matched with a similar range of IOP
levels until 12 mos, an age when levels of IOP start to

Key degenerative features of glaucoma include selective
loss of RGCs, cupping of the optic disc, and degeneration
of the optic nerve. Elevated IOP in wild-type D2 mice (D2.
Jnk2+/+Jnk3+/+) leads to a well-characterized glaucoma
with these key features25. To determine whether D2.
Jnk2−/− and D2.Jnk3−/− mice developed glaucoma, the
gross anatomy of their retinas and optic nerves were
examined. At 6 mos of age, retina and ONH anatomy was
normal in D2.Jnk2−/− and D2.Jnk3−/− eyes (n = 6 eyes/
genotype, Fig. 4a). At 12 mos, D2.Jnk2−/− and D2.Jnk3−/−
eyes with optic nerve degeneration all exhibited the hallmark features of glaucomatous degeneration with no
obvious differences to those observed in D2 mice (n = 6
eyes/genotype, Fig. 4b).
The degree of optic nerve degeneration was determined
in larger numbers of mice by analyzing optic nerve crosssections from mice aged between 9 and 13 mos (see
Materials and methods for details of damage determination). Consistent with IOP elevation, the number of eyes
with optic nerve degeneration increased with age for all
genotypes (Fig. 5). At each time point, there was no

Ofﬁcial journal of the Cell Death Differentiation Association
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Fig. 3 Deﬁciency of Jnk2 or Jnk3 does not alter intraocular pressure proﬁles in D2 mice. IOP elevation occurs in Jnk2 and Jnk3-deﬁcient mice at
8.5 mos a, 10.0 mos b, and 12.0 mos c. IOP elevations sufﬁcient to cause glaucoma were observed in mice of all genotypes. No signiﬁcant differences
were found when comparing Jnk-deﬁcient with control D2 mice (n = 40 per group, P > 0.05 in each comparison. However, at 12 mos Jnk2-deﬁcient
mice tended to have lower IOP than controls (n = 42, P = 0.052). IOP levels start to decline in D2 mice at 12 mos due to ciliary body degeneration
and decreased production of aqueous humor. These data do not exclude a role for JNK2 in lessening this late disease process in the ciliary body, but
this IOP difference may also be due to chance variation. In the boxplot, the boxes deﬁne the 25th and 75th percentiles. The black line in each box
represents the median value. The red diamonds indicate the mean value and the 95% CI. The full range of the data points is also depicted

Fig. 4 Histological assessment of retina and optic nerve. Representative images from H&E-stained ocular cross-sections and PPD stained optic
nerves are shown for unaffected eyes (6 months of age) a, and severely affected eyes (12 months of age) b. These images demonstrate the hallmark
degenerative features of glaucoma including RGC layer (GCL) neuron loss in the retina, nerve ﬁber layer thinning (compare arrowheads in a and b),
optic disc cupping (arrow), and sick and degenerating axons (darkly stained dots), axon loss and glial scarring (asterisks) in the optic nerve. Scale bars:
50 μm (retina), 100 μm (optic nerve head), 25 μm (optic nerve)

signiﬁcant difference in the distribution of injury between
optic nerves from D2.Jnk3−/− and control mice. Thus,
complete absence of Jnk3, either alone or in combination
with a single, heterozygous, null allele of Jnk2, did not
affect optic nerve degeneration. In contrast, in the 9–10
mos group signiﬁcantly more D2.Jnk2−/− optic nerves
Ofﬁcial journal of the Cell Death Differentiation Association

developed glaucomatous damage than control D2 optic
nerves (39% vs. 22% respectively; n = 60 eyes/genotype,
P < 0.001; Fig. 5a). The increased susceptibility was
still present in 10- to 11-month group, with, 73% of
D2.Jnk2−/− eyes having optic nerve damage compared
with 48% of control D2 eyes (n = 80 eyes/genotype,
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Fig. 5 Jnk2 deﬁciency increases optic nerve vulnerability to high IOP. The severity of optic nerve damage was determined using PPD stained
cross-sections (see Materials and methods for details) at 9–10 mos a, > 10–11 mos b, and 12–13 mos c. Nerves were determined to have no
glaucomatous nerve damage (no or early, NOE—no glaucoma based on nerve damage but called NOE as some of these eyes have early
transcriptional changes that precede degeneration30), moderate disease (MOD) or severe disease (SEV). An increased number of eyes from Jnk2 mice
had glaucomatous nerve damage compared with control D2 mice at 9.5 and 10.5 mos. ***P < 1 × 10−5

Fig. 6 Jnk3 deﬁciency subtly exacerbates glaucoma in mice lacking Jnk2. a–c IOP elevations sufﬁcient to cause glaucoma occurred for both
genotypes with no signiﬁcant differences between genotypes at 8 and 10.5 mos. At 12 mos, the difference between Jnk2−/− and Jnk2−/− Jnk3−/−
genotypes was due to the IOP decrease observed in Jnk2 only deﬁcient mice (P = 0.042). The IOP levels in mice with combined Jnk2 and 3
deﬁciencies closely resembled those of wild-type, heterozygous, and Jnk3-deﬁcient mice (compare with Fig. 3c). Thus, the greater decrease in IOP in
the Jnk2−/− mice may be due to chance, as it is hard to reconcile why the additional deﬁciency of Jnk3 in Jnk2−/− Jnk3−/− mutant mice would
prevent it. d-f The severity of optic nerve damage was determined using PPD stained cross-sections (see Materials and methods for details). Data for
D2.Jnk2−/− mice are the same data as in Fig. 5 as mice of all genotypes were produced in the same litters and examined at the same time

P < 0.001, Fig. 5b). In the 12- to 13-month group, a time
point when the vast majority of D2 mice that will develop
glaucomatous neurodegeneration have already done so
(and so used as an end stage)25, there was no difference
between genotypes (n = 45 eyes/genotype, Fig. 5c). Thus,
the absence of Jnk2 is associated with increased susceptibility to ocular hypertension-induced optic nerve damage
(by increasing the likelihood of developing damage at
earlier ages with shorter exposure to high IOP).
Loss of Jnk3 increases optic nerve damage in Jnk2−/− mice

Eyes of D2.Jnk2−/−Jnk3−/− mice developed ocular
hypertension and optic nerve damage consistent with
Ofﬁcial journal of the Cell Death Differentiation Association

glaucoma as for other genotypes (Fig. 6). IOP levels in D2.
Jnk2−/− and D2.Jnk2−/−3−/− mice were closely matched
until 12 mos, when IOP in more D2.Jnk2−/− eyes had
decreased (see above). IOPs proﬁles of D2.Jnk2−/−3−/−
eyes closely resembled those of wild-type, heterozygous,
and D2.Jnk3−/− mice (compare with Fig. 3c). The natural
decline in IOP starting at 12 mos was not affected by
combined Jnk2 and Jnk3 deﬁciency. The combination of
Jnk2 and Jnk3 deﬁciencies had a small effect on optic
nerve damage compared with Jnk2 deﬁciency alone. In
aggregate, between 9 and 13 mos in these age- and sexmatched groups, more D2.Jnk2−/−Jnk3−/− eyes had a
severely damaged optic nerve than D2.Jnk2−/− eyes (107
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Jnk2−/−3−/− compared with 89 Jnk2−/− eyes; n = 185
eyes/genotype, P = 0.007). Based on these data, both Jnk2
and Jnk3 appear to inﬂuence glaucoma pathogenesis in
D2 mice.
JNK2 and JNK3 are not necessary for RGC death in
glaucoma

Recently, Jun deﬁciency was shown to lessen RGC
death after both mechanical optic nerve injury and in
ocular hypertensive D2 mice with optic nerve
damage13,15. Furthermore, after mechanical optic nerve
injury, JUN activation has been shown to be dependent
on JNK2 and JNK313,15. To determine whether Jnk2 and
Jnk3 are required for JUN phosphorylation and RGC
death in glaucoma, we assessed pJUN immunoreactivity
and RGC soma loss in D2.Jnk2−/−Jnk3−/− mice. At 10
mos, we detected pJUN in 6 out of 6 D2.Jnk2−/−Jnk3−/−
retinas and 6 out of 6 control D2 retinas examined
(Fig. 7a). At 12–13 mos, RGC soma loss as assessed by
counts of β-tubulin-positive RGCs was observed in 5 out
of 5 D2.Jnk2−/−Jnk3−/− eyes with severe optic
nerve damage (Fig. 7b). Similar loss of RGC somas
was observed in D2, D2.Jnk2−/−, D2.Jnk3−/−, and
D2.Jnk2−/−Jnk3−/− eyes corresponding with severe
optic nerve damage (Fig. 7c). These results indicate that
complete disruption of Jnk2 and Jnk3 is not sufﬁcient to
prevent JUN activation in RGCs or RGC death after an
ocular hypertensive insult.

Discussion
The stress-activated JNK signaling pathway promotes
neurodegeneration in many systems and, thus, is widely
considered an attractive target for neuroprotective
therapies. The JNK pathway is known to promote axon
degeneration and cause RGC death in settings with acute
axon injury13–18, but was not tested in an age-related,
ocular hypertensive model of glaucoma. Here it is
demonstrated that activation of JNK2 and JNK3 are not
required for glaucomatous degeneration in D2 mice.
Instead, in the absence of JNK2, or both JNK2 and 3, there
is an increase in ocular hypertension-induced neurodegeneration. An important implication of these data is that
in a complex natural disease, manipulating JNK2 has an
impact on disease outcomes unrelated to its role in
directly activating soma or axon degeneration pathways.
The similar localization of pJNK observed in the ONH
after mechanical optic nerve injury14 and in glaucoma
(Fig. 1b) is consistent with the hypothesis that axon injury
activates JNK in glaucoma. The importance of JNK signaling in RGC death in glaucoma and after optic nerve
injury is supported by the increased RGC survival seen in
these same two experimental models in Jun-deﬁcient
mice13,15. Thus, it is surprising that combined Jnk2 and 3
deﬁciencies did not protect RGCs from death in glaucoma
Ofﬁcial journal of the Cell Death Differentiation Association

Fig. 7 JNK2 and JNK3 are not necessary for RGC somal
degeneration in glaucoma. a The JNK target JUN is known to
promote RGC apoptosis in D2 glaucoma15. Double deﬁciency of Jnk2
and Jnk3 did not prevent accumulation of phosphorylated JUN (pJUN)
immunoreactivity (red) at 10 mos. pJUN was detected by
immunoﬂuorescence in retinal ﬂat mounts. b β-Tubulin is an RGCspeciﬁc marker in the retina and was used to label RGCs in retinal ﬂat
mounts at 12 mos. Representative images show loss of RGCs in eyes
with severe optic nerve degeneration compared with healthy (NOE)
eyes. Occasional RGCs have higher β-tubulin immunoreactivity (bright
cells). c Quantiﬁcation of β-tubulin-positive cells suggests that Jnk2
and Jnk3 deﬁciency did not affect somal degeneration of RGCs in eyes
with severe optic nerve loss. RGC counts were similar in NOE eyes for
all genotypes (represented together as All)

as it did after mechanical optic nerve injury. Our analyses
of JNK signaling support the idea that differences occur at
the level of JUN activation. Whereas JUN activation
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appears to be dependent on Jnk2 and 3 after mechanical
optic nerve injury13, JUN activation due to ocular hypertension in D2 mice still occurred in RGC somas in the
absence of JNK2 and 3 (Fig. 7a). The antibody used in this
study detected JUN phosphorylation at the serine 63
residue, a phosphorylation site that is primarily speciﬁc to
the kinase activity of JNK1, JNK2, and JNK3 after
insults31. These data show that JNK2 and 3 are not
required for JUN activation within RGCs, and they suggest a role for JNK1 in glaucoma. It is unclear if the
involvement of JNK1 speciﬁc to D2 glaucoma is the result
of the differing nature of the insult (progressive, chronic
ocular hypertension compared with acute and sudden
mechanical axonal injury), the potential for ocular
hypertension to directly perturb pathways in more than
just RGC axons, the involvement of other cells besides
RGCs, or the absence of JNK2 and 3. In future studies, it
will be important to understand why the mechanism of
JUN activation appears to differ between the contexts of a
natural, age-related, progressive ocular hypertensive
injury and an experimentally induced mechanical axonal
injury. Nevertheless, these data highlight the importance
of testing neuroprotective treatments in an age-related,
chronic, ocular hypertensive model of glaucoma.
This work uncovered a novel neuroprotective function
of JNK2 and provided an example of unequal contributions by JNK2 and JNK3 to glaucoma pathogenesis. Here,
mice completely deﬁcient in Jnk2 progressed more quickly
from onset of ocular hypertension to glaucomatous neurodegeneration than wild-type, Jnk2 and Jnk3 double
heterozygous, or Jnk3-deﬁcient mice. Although unlikely,
as no heterozygous effects are reported, smaller effects
associated with copy number of Jnk2 and Jnk3 cannot be
dismissed due to the inclusion of Jnk2 or Jnk3 heterozygous mice in the study. Combining Jnk2 and Jnk3
deﬁciencies did have a small additional effect on optic
nerve damage above the level of Jnk2 deﬁciency. Overall,
these data are consistent with JNK2 being a major mediator of neuroprotective JNK signaling after an ocular
hypertensive injury. The prominent role of JNK2 may be
related to a function of JNK2 that is not currently associated with other JNKs. Our data indicate that Jnk2 was
signiﬁcantly downregulated in RGCs at a pre-degenerative
stage of glaucoma in D2 mice (Fig. 1a). This early stage is
marked by transcriptional responses related to metabolic
and mitochondrial dysfunction within RGCs29,32–34. Of
note, a unique function of JNK2 is to regulate mitophagy,
in part through controlling degradation of smARF (a gene
product of Cdnk2b) and indirectly p6235. Complete loss of
JNK2 in RGCs may disrupt mitophagy early in glaucoma.
Alternatively, JNK-deﬁcient mice have altered immune
responses36–38 and inﬂammatory responses in the nervous
system39,40. Thus, disruption of Jnk2 may affect how these
types of responses contribute to glaucoma pathogenesis.
Ofﬁcial journal of the Cell Death Differentiation Association
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In the experiments described here, mice carried a germline disruption of Jnk2. As the expression of Jnk2 is ubiquitous in mammalian cells41, its absence may have
affected the development, physiology, or stress response
in any glaucoma-relevant cell type. Experiments that use
cell type-speciﬁc disruption of Jnk2 in RGCs and other
glaucoma-relevant cells are necessary to further understand the role of JNK2 as a susceptibility factor for
glaucoma.
In conclusion, this study provides further evidence
implicating stress-activated kinases in the JNK family as
modulators of RGC survival or death after axon injury and
in glaucoma. The speciﬁc mechanisms that are impacted
by the injury type and the ﬁnal outcome is likely to be
impacted by the competing pro-survival and pro-death
effects of JNK activation. To effectively target JNK as a
neuroprotective therapy, the pleiotropic effects of JNK
isoforms need to be identiﬁed and speciﬁcally targeted.

Materials and methods
Mice

All experiments were conducted in accordance with the
Association for Research in Vision and Ophthalmology
statement on the use of animals in ophthalmic research
and approved by The Jackson Laboratory Institutional
Animal Care and Use Committee. Mice were housed with
a 14-h light/10-h dark cycle and provided food and water
ad libitum42. DBA/2J (D2), D2-Gpnmb+/J (D2-Gpnmb+),
and mice carrying null alleles of Jnk2 (Jnk2-; D2.129(B6)Mapk9<tm1Flv>/SjJ) and Jnk3 (Jnk3-; D2.129S1(B6)Mapk10<tm1Flv>/SjJ) backcrossed to D2 for 13 generations
have been previously described4,13,24,43. D2-Gpnmb+ mice
are a substrain of D2 mice that have normal IOP at all
ages and do not develop glaucoma44. Experimental
cohorts of mice were generated using intercrosses of D2.
Jnk2+/- Jnk3+/- (double heterozygous) mice. Mice referred
to as control D2 mice include mice with wild-type (+/+)
and heterozygous (+/-) genotypes for Jnk2 and Jnk3 (e.g.,
Jnk2+/+Jnk3+/+, Jnk2+/+Jnk3+/−, Jnk2+/−Jnk3+/+, and
Jnk2+/−Jnk3+/−). Mice with genotypes of Jnk2−/− include
mice with Jnk3+/+ and Jnk3+/− genotypes. Mice with
genotypes of Jnk3−/− include mice with Jnk2+/+ and
Jnk2+/- genotypes.
Clinical exams and intraocular pressure measurement

D2 mice develop a form of pigmentary glaucoma. In D2
eyes, elevated IOP occurs secondary to a depigmenting
iris disease24,25,42. Iris disease and intraocular pressure
were evaluated in mutant mice and littermate control D2
mice using previously described methods23,24,45. Iris disease was assessed at 2-month intervals starting at
6 months of age until experimental completion in > 40
eyes of each genotype. Intraocular pressure was measured
at 8.5, 10.0, and 12.0 months of age.
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Assessment of retina and optic nerve damage by histology

Mice were analyzed as three age groups: 9–10 mos,
>10–11 mos, and 12–13 mos. Mice of each genotype
within each age bin were age and sex matched. The
method of preparing, staining, and analyzing plastic sections of retinas and optic nerves for damage has been
previously described and validated4,8,25,30,46,47. Retinal
cross-sections were stained with hematoxylin and eosin
(H&E). Cross-sections of optic nerve were stained with
paraphenylenediamine (PPD), which stains all myelin
sheaths, but darkly stains the axoplasm of injured or dying
axons. Individual damaged axons are readily identiﬁed
within a generally healthy nerve. Two investigators
assigned one of three damages level to each nerve. The
investigators were masked to age, genotype, and damage
level assigned by the other investigator. In rare cases of
disagreement, a third masked investigator acted as a tiebreaker. Nerves with no or early glaucoma (NOE) have no
detectable glaucomatous damage and are indistinguishable from D2.Gpnmb+ nerves. Moderately (MOD) affected nerves had readily detectable degenerating axons
(average 30% axon loss) as marked by darkly stained
axoplasm; however, the majority of axons were still
healthy. Severely (SEV) affected nerves have >50% axon
loss and prominent gliosis. Axon numbers are signiﬁcantly different between optic nerves of each damage
level4,8,25,30,46,47. To be used for histology or RGC counts
representing severe glaucoma, a retina had to be associated with an optic nerve judged to have >95% of axons
lost (i.e., entirely gliotic with few remaining axons).
Immunohistochemistry

Eyes were ﬁxed in 4% paraformaldehyde and subsequently either cryoprotected in 30% sucrose and frozen or
the retinas were dissected for use in ﬂat mounts. For
cryosection immunostaining, slides were blocked in 10%
horse serum in 0.1% Triton X-100 in phosphate-buffered
saline (PBS) (PBST) for 2 h, incubated in primary antibody
solutions overnight, and secondary antibody solutions for
2 h. Primary antibodies (rabbit anti-phosphorylated panJNK, pJNK, Cell Signaling, #4668) were diluted in PBST
containing 2% goat serum. Alexaﬂuor-conjugated secondary antibodies (Invitrogen) were diluted in PBST
(AF488 and AF568) and nuclei were counterstained with
4,6-diamidino-2-phenylindole (DAPI). For ﬂat mount
immunostaining, retinas were blocked in 0.3% Triton X100 in PBS containing 10% goat serum for 3–4 h, incubated in primary antibody solutions overnight and secondary antibody solutions for 3–4 h. Primary antibodies
(rabbit anti-p-cJUN, Abcam, #ab32385, mouse anti-βtubulin, Covance, #MMS-435P) were diluted in 0.3%
Triton X-100 in PBS, and Alexaﬂuor-conjugated secondary antibodies (Invitrogen) diluted in PBST for 24 h at
4°C. Following antibody incubations and washes, the
Ofﬁcial journal of the Cell Death Differentiation Association
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retinas were mounted on slides in aquamount, coverslipped, and sealed with nail polish. Images of slides were
taken using a Zeiss AxioImager.
RNA-sequencing dataset analysis

The RGC transcriptome data used was from publically
available RNA-sequencing data sets generated by our lab:
GEO accession number GSE9065429. Differential gene
expression analysis was performed in edgeR v3.10.548 and
plotted using custom R scripts.
Statistical analyses

For IOP measurements, 40 eyes per genotype were
assessed at each time point. Statistical analysis was performed using Student’s t-test and Holm-corrected
P-values with P < 0.01 considered signiﬁcant. Optic nerve
disease stage proﬁles were compared between genotypes
using Fisher exact and Holm-corrected P-values with
P < 0.01 considered signiﬁcant. Differential expression
analysis of RNA-seq transcripts was adjusted for multiple
testing using a FDR (q). Genes were considered to be
signiﬁcantly differentially expression at an FDR < 0.05.
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